Xella Health raises $3.7m pre-seed to build menstrual blood–based precision health platform
Ahead of a Spring 2026 launch the start-up is targeting a 10,000 women waitlist
Xella Health, a women’s precision health and telemedicine company, has closed more than $3.7 million in pre-seed funding as it prepares to launch a new diagnostics-led platform built around an underused biological sample: menstrual blood.
The round was led by Precursor Ventures, with participation from Capital F, Ulu Ventures, and a group of strategic angel investors spanning healthcare, diagnostics, and consumer technology.
Xella positions itself as building a new category of women’s health - one that moves away from episodic, symptom-led care and toward continuous biological insight across life stages, from fertility through perimenopause and beyond. Central to that vision is the use of menstrual fluid alongside traditional blood testing, combined with longitudinal data analysis and clinician-led guidance.
Ahead of its planned Spring 2026 launch, Xella says it is on pace to attract more than 10,000 women to its waitlist, signaling strong appetite for a more modern, data-driven approach to women’s health.
The start-up was co-Founded by industry experts, Kelly Lacob, CEO (2x Stanford, Johns Hopkins, former Mammoth Biosciences), Adriana Dantas, COO (former Roche, BD), and Jesus Ching, PhD, CTO (former Mammoth Biosciences, Arc Bio).
“Our mission is to give women the answers and care they have always deserved,” said Kelly Lacob, Co-Founder & CEO of Xella.
“Xella is building the infrastructure to decode female biology–getting to the root cause of conditions that uniquely, differently or disproportionately affect women, many of which suffer from an unacceptably poor standard of care today. This funding allows us to accelerate product development and prepare for our first launch.”
Moving diagnostics beyond peripheral blood
Menstrual blood has long been treated as waste rather than data. Xella argues that this has left valuable biological signals untapped—particularly for conditions that disproportionately affect women and are often slow to diagnose.
By analysing menstrual fluid in combination with peripheral blood, the company says it can surface insights related to menstrual irregularities, chronic pelvic pain, fertility markers such as egg quality and quantity, miscarriage risk, perimenopause staging, hormone replacement therapy (HRT) guidance, genetic predispositions for reproductive cancers, and broader markers of biological ageing.
Instead of one-off tests, Xella is building a system designed to track changes over time, pairing multi-omic diagnostics with clinical interpretation. Each user works with a dedicated clinician-coach, supported by AI tools, to translate complex biological data into practical next steps.
“Every woman who comes to Xella works with a dedicated clinician-coach, supported by AI, to ensure that the complex data we analyze translates into meaningful, actionable health outcomes rather than more noise” said Kelly Lacob.
The new capital will be used to finalize product development, expand strategic partnerships, and support Xella’s upcoming market launch.
“Xella represents the future of proactive, personalized care enabled at scale by AI—where early detection can meaningfully change outcomes for women by going after one of the largest unsolved problems in healthcare—early, personalized detection for women,” said Margaret Coblentz, Co-Founder and General Partner at Capital F.